Empowered Patient Podcast
Developing Potent Oral Kinase Inhibitor to Treat Recurrent Difficult to Treat Brain Cancer with Scott Megaffin Adastra Pharmaceuticals
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:16:27
- More information
Informações:
Synopsis
Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas. He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well. #Glioblastoma #braintumor #drugdevelopment #braincancer #NCI AdastraRx.com Download the transcript here
